Editorial: Spoilt? Pharma? Surely Some Mistake
This article was originally published in Scrip
Executive Summary
Some people reckon that what others say of us is none of our business. It's a useful maxim for retaining sanity in the Twitter and Google age, but perhaps there are times when a bit of constructive criticism is good for the soul. We all know that the public perception of the pharma industry isn't great, but the opinions of an Ivy League economics professor laid out in a recent JAMA Forum commentary may sting. Paraphrasing, it seems Professor Uwe Reinhardt thinks you're a bit spoilt: fragile little birds shielded by government from the harsh realities of the free market, and enjoying monopoly positions. He's got a point.
You may also be interested in...
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.